Imaging-guided vs standard treatment for psoriatic arthritis
Part of Bones, joints & muscles, Skin clinical trials.
This study compares two “treat-to-target” strategies for psoriatic arthritis. One strategy uses imaging to guide treatment changes, and the other uses standard clinic assessments, to see which approach controls symptoms more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (over 18).
- You have a confirmed diagnosis of psoriatic arthritis (PsA) using the CASPAR criteria.
- Your doctor says you need disease-modifying medicine (DMARDs), and you’ve tried at least two NSAID medicines for a total of 4 weeks or more for mainly spine/joint-tendon problems.
- Your arthritis symptoms started within the last year (no verified arthritis more than 1 year before joining).
- You have NOT previously taken DMARDs for psoriatic arthritis.
- You can safely have MRI scans, and you do not have serious conditions that would prevent following the study plan (like uncontrolled major illnesses, recent serious infections, or problems with treatment adherence).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
This trial compares two medicines for people with psoriatic arthritis who still have joint, skin, or nail symptoms after methotrexate. One medicine is apremilast (a pill), and the other is adalimumab (an injection). The study aims to see which works better.
This Phase 3 study compares two biologic medicines—guselkumab and golimumab—to see which works better for people with active psoriatic arthritis. It is designed for people whose psoriatic arthritis did not respond well to a prior “TNF-blocking” medicine (or lost response).
This study looks at how well advanced treatments work for people with psoriatic arthritis, and whether results differ for sex and gender. You may be eligible if your psoriatic arthritis is active and you are planning to start an advanced treatment for symptoms in the joints and surrounding areas.
This study follows patients with inflammatory arthritis (rheumatoid arthritis or spondyloarthritis) to learn more about how well biologic or targeted therapies work. If you have tried standard treatments without enough relief, this may help researchers improve future care.
This trial tests a new drug called picankibart to see if it helps people with active psoriatic arthritis who haven't gotten enough relief from standard treatments like NSAIDs or non-biologic DMARDs. It may be an option if you have at least 3 tender and 3 swollen joints and active or past plaque psoriasis.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.